Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coordinated immune-epithelial dynamics in the nasal epithelium protect against respiratory virus infection.

bioRxiv : the preprint server for biology·2026
Same author

Reactive and therapy induced bone marrow changes linked to systemic infectious and non-infectious disorders including MAS/HLH report from the European association for haematopathology, Dubrovnik 2024.

Virchows Archiv : an international journal of pathology·2026
Same author

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026
Same author

Mast Cells in Acute COVID-19 Patients.

Allergy·2026
Same author

The genetic landscape of extramedullary plasmacytoma: a comparative analysis with extramedullary disease of multiple myeloma.

Haematologica·2026
Same author

Myeloid/lymphoid precursor cell neoplasms and mixed phenotype acute leukemias: A Bone Marrow Workshop Report from the 22nd European Association for Hematopathology/Society of Hematopathology Meeting, Dubrovnik, 2024.

American journal of clinical pathology·2026

Related Experiment Video

Updated: Jun 5, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Targetable molecular pathways in classical Hodgkin's lymphoma.

Heiner Adams1, Ellen C Obermann, Stephan Dirnhofer

  • 1University Hospital Zurich, Institute for Pathology, Switzerland.

Expert Opinion on Investigational Drugs
|January 6, 2011
PubMed
Summary

Targeting molecular pathways offers new hope for classical Hodgkin's lymphoma (cHL) patients who do not respond to or relapse after standard treatment. Novel agents may overcome treatment resistance and reduce late toxicities in cHL.

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Related Experiment Videos

Last Updated: Jun 5, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Most classical Hodgkin's lymphoma (cHL) patients achieve cure with current therapies.
  • A subset of patients experiences refractory disease or relapse, necessitating alternative treatment strategies.
  • Late toxicities from aggressive treatments pose challenges for long-term survivors.

Purpose of the Study:

  • To review critical molecular pathways implicated in cHL pathogenesis.
  • To explore novel therapeutic agents targeting these pathways.
  • To provide insights into ongoing clinical trials of these novel agents.

Main Methods:

  • Comprehensive literature search of PubMed and clinical trial data up to August 2010.
  • Expert review of crucial molecular pathways in cHL.
  • Discussion of novel agents and their potential clinical applications.

Main Results:

  • Key oncogenic pathways in cHL include loss of B-cell identity, NF-κB activation, and JAK2-STAT pathway activation.
  • Novel therapeutic strategies focus on inhibiting these identified molecular targets.
  • Current clinical trials are evaluating the efficacy of these targeted agents.

Conclusions:

  • Targeting specific molecular pathways presents a promising strategy for refractory/relapsed cHL.
  • Monoclonal antibodies and small-molecule inhibitors show potential for cHL treatment.
  • Further research and clinical trials are essential to optimize targeted therapies for cHL.